Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Satellos Bioscience Inc ICOTF


Primary Symbol: T.MSCL Alternate Symbol(s):  MSCLF

Satellos Bioscience Inc. is a Canada-based a drug discovery and development company with a focus on muscle regeneration. The Company is focused on developing medicines to treat degenerative muscle conditions. Its MyoReGenX platform is specifically designed to recreate the specialized muscle stem cell niche in vitro. MyoReGenX platform enables to map pathways which modulate muscle repair and regeneration, identify, and confirm drug targets, and test drug candidates for their ability to restore muscle stem cell repair mechanisms that have been impaired by genetic mutations, disease or injury. Its lead program is an oral, small molecule drug candidate in development as a disease-modifying treatment for Duchenne muscular dystrophy. Its iCo portfolio includes Oral Amp B Delivery System, a patented oral transport technology and Bertilimumab a human monoclonal eotaxin antibody with potential to treat a range of allergic and inflammatory conditions mediated by eotaxin-1.


TSX:MSCL - Post by User

Post by MountainMasteron Jul 11, 2018 2:08pm
166 Views
Post# 28301240

News and Results

News and Results I spoke with Mike Liggett on Tuesday morning. He informed me and others that took the time to contact him, that the pharmacokinetic results and other related news will be released sometime this week. The company has released news on Wednesdays in the past so I suspect a lot of investors thought it would be today as well, hence the solid trading yesterday.
I personally feel that releasing news on Friday is not the greatest idea so my guess would be tomorrow, Thursday. 
In no way am I management, I'm just an investor that took the time to call to get some information. It clearly states in the last news release that the results would be released in the weeks to come so this week is the week. 
No he didn't say anything about the results or news but speaking with him was like speaking to a 16 year old who just got their drivers licence, you could hear and feel the excitement.

Contact info which is public:

Mike Liggett
Chief Financial Officer
778 802-9806
liggett@icotherapeutics.com
<< Previous
Bullboard Posts
Next >>

USER FEEDBACK SURVEY ×

Be the voice that helps shape the content on site!

At Stockhouse, we’re committed to delivering content that matters to you. Your insights are key in shaping our strategy. Take a few minutes to share your feedback and help influence what you see on our site!

The Market Online in partnership with Stockhouse